These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11864720)

  • 1. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD.
    Swanson JM; Volkow ND
    Behav Brain Res; 2002 Mar; 130(1-2):73-8. PubMed ID: 11864720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of methylphenidate: insights from PET imaging studies.
    Volkow ND; Fowler JS; Wang G; Ding Y; Gatley SJ
    J Atten Disord; 2002; 6 Suppl 1():S31-43. PubMed ID: 12685517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate.
    Cheon KA; Ryu YH; Kim JW; Cho DY
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):95-101. PubMed ID: 15572278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
    Anderson VR; Scott LJ
    Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum and brain concentrations of methylphenidate: implications for use and abuse.
    Swanson JM; Volkow ND
    Neurosci Biobehav Rev; 2003 Nov; 27(7):615-21. PubMed ID: 14624806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter genotype and methylphenidate dose response in children with ADHD.
    Stein MA; Waldman ID; Sarampote CS; Seymour KE; Robb AS; Conlon C; Kim SJ; Cook EH
    Neuropsychopharmacology; 2005 Jul; 30(7):1374-82. PubMed ID: 15827573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
    Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH
    Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence.
    Crunelle CL; van den Brink W; Veltman DJ; van Emmerik-van Oortmerssen K; Dom G; Schoevers RA; Booij J
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1714-23. PubMed ID: 23731497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review.
    Contini V; Rovaris DL; Victor MM; Grevet EH; Rohde LA; Bau CH
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):555-60. PubMed ID: 22709890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
    McBurnett K; Starr HL
    Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder.
    Roman T; Szobot C; Martins S; Biederman J; Rohde LA; Hutz MH
    Pharmacogenetics; 2002 Aug; 12(6):497-9. PubMed ID: 12172219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and clinical effectiveness of methylphenidate.
    Kimko HC; Cross JT; Abernethy DR
    Clin Pharmacokinet; 1999 Dec; 37(6):457-70. PubMed ID: 10628897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Childress A; Belchenko D; Lempa B
    Expert Rev Neurother; 2017 Feb; 17(2):113-121. PubMed ID: 27936986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD.
    Gomeni R; Bressolle-Gomeni F; Spencer TJ; Faraone SV; Fang L; Babiskin A
    Clin Pharmacol Ther; 2017 Dec; 102(6):951-960. PubMed ID: 28369788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate.
    Krause KH; Dresel S; Krause J; Kung HF; Tatsch K; Lochmüller H
    J Neurol; 2002 Aug; 249(8):1116-8. PubMed ID: 12420715
    [No Abstract]   [Full Text] [Related]  

  • 20. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.